Effect of Adaptive Servoventilation on Cardiac Function in Chronic Heart Failure and Cheyne-Stokes Respiration

NCT ID: NCT01212705

Last Updated: 2010-10-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sleep disordered breathing is common in patients with chronic heart failure. Adaptive servoventilation is a novel method of treatment central sleep apnoea, especially associated with Cheyne-Stokes-respiration. The aim of the study is to investigate effect of adaptive servoventilation on cardiac function, exercise tolerance and quality of life in patients with chronic heart failure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Heart Failure Central Sleep Apnea Cheyne-Stokes Respiration

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ASV

Group Type EXPERIMENTAL

Adaptive servoventilation

Intervention Type DEVICE

Background expiratory positive airway pressure with some inspiratory pressure support when needed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adaptive servoventilation

Background expiratory positive airway pressure with some inspiratory pressure support when needed

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* chronic heart failure with ejection fraction ≤45%
* optimal medical treatment for at least 1 month
* clinical diagnosis of Cheyne-Stokes respiration

Exclusion Criteria

* unstable heart failure
* stroke
* transient ischemic attack in last 6 months
* pacemaker, cardioverter-defibrillator or resynchronization device implanted less than 6 months before study entrance
* severe chronic obstructive pulmonary disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Military Institute od Medicine National Research Institute

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anna Kazimierczak

Role: PRINCIPAL_INVESTIGATOR

Military Institute of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Military Institute of Medicine

Warsaw, Szaserow 128, Poland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Poland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anna Kazimierczak

Role: CONTACT

48 22 6818017

Krystian Krzyzanowski

Role: CONTACT

48 512 356 207

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BW2126/10

Identifier Type: -

Identifier Source: org_study_id